Pan-cancer expression analysis was performed for GZMB, which showed its significantly high expression in cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), esophageal carcinoma (ESCA), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), kidney renal clear cell carcinoma (KIRC), rectum adenocarcinoma (READ), stomach adenocarcinoma (STAD), and UCEC tissues, while significantly low expression was observed in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) tissues (Figure 7A). Here, GZMB is linked to lung adenocarcinoma.